{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T14:38:27Z","timestamp":1722263907212},"reference-count":19,"publisher":"Korean Association of Internal Medicine","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Korean J Intern Med"],"DOI":"10.3904\/kjim.2000.15.2.122","type":"journal-article","created":{"date-parts":[[2015,7,30]],"date-time":"2015-07-30T03:05:29Z","timestamp":1438225529000},"page":"122-126","source":"Crossref","is-referenced-by-count":1,"title":["Topotecan - Based Combination Chemotherapy in Patients with Transformed Chronic Myelogenous Leukemia and Advanced Myelodysplastic Syndrome"],"prefix":"10.3904","volume":"15","author":[{"given":"Soo Jeong","family":"Park","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong Wook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hee Je","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyeon Seok","family":"Eom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang Ki","family":"Min","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong Wook","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Woo Sung","family":"Min","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun Choo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2270","published-online":{"date-parts":[[2000,7,31]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.bi.58.070189.002031"},{"key":"ref2","first-page":"907","volume-title":"Camptothecin induction of a time-and concentration-dependent decrease of topoisomerase I and its implication in camptothecin activity","author":"Beidler","year":"1995"},{"key":"ref3","first-page":"1235","volume-title":"Preclinical studies of water-insoluble camptothecin congeners: Cytotoxicity, development of resistance, and combination treatment","author":"Pantazis","year":"1995"},{"key":"ref4","first-page":"431","volume-title":"Synergistic cytotoxicity with combined inhibition of topoisomerase (Topo) I and II","author":"Anzai","year":"1992"},{"key":"ref5","first-page":"2473","volume-title":"Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia","author":"Beran","year":"1996"},{"key":"ref6","volume-title":"Multilevel therapeutic targeting by topoisomearse inhibitors. [Review]","author":"Smith","year":"1994"},{"key":"ref7","first-page":"1857","volume-title":"A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes","author":"Cheson","year":"1986"},{"key":"ref8","first-page":"51","volume-title":"5-Aza-2\u2032-deoxycytidine (decitabine) and 5-azacytidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: Past, present and future trends","author":"Pinto","year":"1993"},{"key":"ref9","first-page":"2180","volume-title":"Synergistic cytotoxicity with 2\u2032-deoxy-5-azacytidine and topotecan in vitro and in vivo","author":"Anzai","year":"1992"},{"key":"ref10","first-page":"647","volume-title":"Phase I and pharmacologic study of topotecan: A novel topoisomerase I inhibitor","author":"Rowinsky","year":"1992"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-199208000-00004"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.18.1499"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-199408000-00002"},{"key":"ref14","first-page":"1146","volume-title":"Phase I study of topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia","author":"Kantarjian","year":"1993"},{"key":"ref15","first-page":"2193","volume-title":"Phase I and pharmacodynamic study of the topoisomerase I - inhibitor topotecan in patients with refractory acute leukemia","author":"Rowinsky","year":"1994"},{"key":"ref16","volume-title":"","author":"Chabner","year":"1996"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/88.11.734"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19861101)58:9<2023::AID-CNCR2820580912>3.0.CO;2-H"},{"key":"ref19","volume-title":"","year":"1998"}],"container-title":["The Korean Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.kjim.org\/upload\/kjim-15-2-122-4.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,20]],"date-time":"2019-08-20T05:51:14Z","timestamp":1566280274000},"score":1,"resource":{"primary":{"URL":"http:\/\/kjim.org\/journal\/view.php?doi=10.3904\/kjim.2000.15.2.122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,7,31]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2000,7,30]]}},"URL":"https:\/\/doi.org\/10.3904\/kjim.2000.15.2.122","relation":{},"ISSN":["1226-3303","2005-6648"],"issn-type":[{"value":"1226-3303","type":"print"},{"value":"2005-6648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,7,31]]}}}